by Mark Chiang

马克·蒋

Share To

分享到

Almirall has identified a second dermatology target as part of its ongoing drug discovery collaboration with Absci. This development follows the successful delivery of AI-designed, functional antibody leads for the first target addressed in their partnership. The collaboration focuses on leveraging artificial intelligence to accelerate the discovery and design of therapeutic antibodies for dermatological conditions..

Almirall在其与Absci持续的药物发现合作中，确定了第二个皮肤病学靶点。这一进展是在他们合作中针对第一个靶点成功交付由人工智能设计的功能性抗体先导物之后取得的。该合作聚焦于利用人工智能加速皮肤病治疗抗体的发现与设计。

The initial phase of the partnership demonstrated progress in utilizing AI technology to generate functional antibody candidates, marking a significant milestone in their joint efforts. With this success, Almirall has now selected a new target within the field of dermatology to further explore potential treatments using Absci’s AI-driven platform.

合作伙伴关系的初始阶段展示了利用人工智能技术生成功能性抗体候选物的进展，标志着他们共同努力的一个重要里程碑。基于这一成功，Almirall现已在皮肤病学领域选择了一个新目标，以进一步探索使用Absci的AI驱动平台开发潜在治疗方法。

Both companies aim to continue advancing research and development in this area, applying innovative approaches to address unmet medical needs..

两家公司都旨在继续推进该领域的研发，采用创新方法来满足未被满足的医疗需求。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: August 8, 2025

日期：2025年8月8日

Related posts:

相关帖子：

Biosimilar Efficacy: Manufacturers Navigate FDA and EMA Guidelines for Clinical Trial Design

生物仿制药疗效：制造商遵循FDA和EMA指南进行临床试验设计

Calley Means Contributes to Presidential Commission Report on Childhood Chronic Diseases

卡利·米恩斯为总统委员会关于儿童慢性病的报告做出了贡献。

Independent Pharmacies Gain Ground in Exclusive Specialty Drug Networks, 2025 Report Shows

2025年报告显示，独立药房在独家专科药物网络中取得进展

MYCN Oncogene Linked to Aggressive Neuroblastoma and Therapy Resistance in Children

MYCN致癌基因与儿童侵袭性神经母细胞瘤及治疗耐药性相关

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

电子邮件地址

Author

作者

Mark Chiang

蒋扬标记

Related Post

相关内容

News Flash

新闻快讯

HHS Terminates mRNA Vaccine Contracts Citing Studies on Potential Adverse Effects

美国卫生与公众服务部因潜在不良反应研究终止mRNA疫苗合同

2025-08-08

2025年8月8日